[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

World Biosimilars Market Explored by Kuick Research in Its Report Published at MarketPublishers.com

08 Sep 2014 • by Natalie Aster

LONDON – At present, the evolution of biosimilars has already reached various stages worldwide. Duу to diverse regulatory frameworks and variable clarity in the guidelines, different definitions of biosimilars have emerged in various countries. Until the present day, Europe has the best-established framework for biosimilars. Currently, the USA is almost aligned to the European standards.

The monoclonal antibodies (mAbs) and insulin segments are predicted to see the maximum growth, and by 2018 these segments are poised to account for a share of 40% of the overall biosimilars market. Moreover, with mAbs possessing one of the strongest research and development pipeline in the world biologics market, it is forecast to witness the introduction of numerous novel next-generation technologies, which are likely to push mAbs therapeutics into newer areas like neurological and cardiovascular disorders, and solid tumors. As for innovations, the biosimilars market is expected to see the introduction of low molecular weight heparins, follitropins and interferons, additionally to mAbs. Some pharmaceutical companies will likely start focusing on specific therapeutic areas basing on their strategic fit and manufacturing capacity.

New comprehensive research report “Global Biosimilars Market Regulations & Pipeline Insight” prepared by Kuick Research provides access to a detailed overview of the worldwide biosimilars market scenario. It presents an in-depth insight into the biosimilars pipeline as well as draws up a clear picture of the regulative framework.

The topical study gives insightful analysis of 12 regional and country markets; contains an extensive biosimilars pipeline assessment by indication, phase, country and company; and sheds light on 276 various biosimilars currently in development phase, 76 biosumilars in pre-clinical phase and 113 marketed biosimilars.  Besides, the report offers a holistic view of the market dynamics, gives attention to all important industry related issues, points out the major growth opportunities emerging in the global biosimilars market, looks deep into the competitive landscape and also provides valuable data on the top companies engaged in the world biosimilars industry.

Report Details:

Global Biosimilars Market Regulations & Pipeline Insight
Published: September, 2014
Pages: 836
Price: US$ 2,400.00 

Other Recent Topical Reports by Kuick Research Include:

More new research reports by the publisher can be found at Kuick Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest